CN119300827A - Mglur5调节化合物、组合物及使用方法 - Google Patents

Mglur5调节化合物、组合物及使用方法 Download PDF

Info

Publication number
CN119300827A
CN119300827A CN202380041964.8A CN202380041964A CN119300827A CN 119300827 A CN119300827 A CN 119300827A CN 202380041964 A CN202380041964 A CN 202380041964A CN 119300827 A CN119300827 A CN 119300827A
Authority
CN
China
Prior art keywords
compound
degrees
solvate
solvate form
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380041964.8A
Other languages
English (en)
Chinese (zh)
Inventor
T·R·西格特
S·斯特里特马特
F·斯卡拉维利
C·科拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alex Medical Co
Yale University
Original Assignee
Alex Medical Co
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alex Medical Co, Yale University filed Critical Alex Medical Co
Publication of CN119300827A publication Critical patent/CN119300827A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202380041964.8A 2022-03-22 2023-03-22 Mglur5调节化合物、组合物及使用方法 Pending CN119300827A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263322446P 2022-03-22 2022-03-22
US63/322446 2022-03-22
PCT/US2023/015966 WO2023183428A1 (en) 2022-03-22 2023-03-22 Mglur5 modulating compounds, compositions, and methods of use

Publications (1)

Publication Number Publication Date
CN119300827A true CN119300827A (zh) 2025-01-10

Family

ID=88101942

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380041964.8A Pending CN119300827A (zh) 2022-03-22 2023-03-22 Mglur5调节化合物、组合物及使用方法

Country Status (9)

Country Link
US (1) US20250230149A1 (https=)
EP (1) EP4496572A4 (https=)
JP (1) JP2025509988A (https=)
KR (1) KR20250008042A (https=)
CN (1) CN119300827A (https=)
AU (1) AU2023238896A1 (https=)
CA (1) CA3246263A1 (https=)
IL (1) IL315809A (https=)
WO (1) WO2023183428A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080252A1 (en) * 2023-10-13 2025-04-17 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2025188734A1 (en) * 2024-03-06 2025-09-12 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691821B2 (en) * 2010-11-11 2014-04-08 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5

Also Published As

Publication number Publication date
WO2023183428A8 (en) 2023-12-14
AU2023238896A1 (en) 2024-10-03
KR20250008042A (ko) 2025-01-14
CA3246263A1 (en) 2023-09-28
EP4496572A1 (en) 2025-01-29
US20250230149A1 (en) 2025-07-17
JP2025509988A (ja) 2025-04-11
EP4496572A4 (en) 2026-03-11
WO2023183428A1 (en) 2023-09-28
IL315809A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
US10584122B2 (en) Solid forms of a compound modulating kinases
CN101406473A (zh) 二氢嘧啶化合物的用途及含其的药物组合物
TW201444834A (zh) 選擇性ｃｄｋ４／６抑制劑之固態形式
WO2004022538A1 (ja) 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬
CN119300827A (zh) Mglur5调节化合物、组合物及使用方法
US12115167B2 (en) Oral formulations of fasudil with ion exchange resin
IL268092B2 (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
WO2020072796A1 (en) Crystalline forms of niraparib freebase
JP7048629B2 (ja) 医薬組成物およびその使用
KR102399374B1 (ko) 알츠하이머병의 치료를 위한 ｎ-[2-(6-플루오로-1ｈ-인돌-3-일)에틸]-3-(2,2,3,3-테트라플루오로프로폭시)벤질아민 히드로클로라이드의 신규한 다형체 형태
WO2025080252A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
AU2023468841A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2024027752A1 (zh) 包含杂环化合物的药物组合物及其制备方法和应用
WO2025188734A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
HK1248223B (en) Solid forms of a compound modulating kinases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination